These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 37415733)
41. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349 [TBL] [Abstract][Full Text] [Related]
42. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
43. PARP Inhibitors for Cancer Therapy. Lin KY; Kraus WL Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401 [TBL] [Abstract][Full Text] [Related]
44. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Onstad M; Coleman RL; Westin SN Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746 [TBL] [Abstract][Full Text] [Related]
45. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors. Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200 [TBL] [Abstract][Full Text] [Related]
46. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. Cheng X; Zhang B; Guo F; Wu H; Jin X Mol Oncol; 2022 Apr; 16(7):1591-1607. PubMed ID: 34854226 [TBL] [Abstract][Full Text] [Related]
53. The DNA damaging revolution. Cetin B; Wabl CA; Gumusay O Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228 [TBL] [Abstract][Full Text] [Related]
54. Recent advances in cancer therapy using PARP inhibitors. Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646 [TBL] [Abstract][Full Text] [Related]
55. PARP inhibitors diminish DNA damage repair for the enhancement of tumor photodynamic therapy. Lei S; Ge F; Lin M; Wang X; Shen J; Yang Y; Deng J; Wang Z; Wang J; Li K Photodiagnosis Photodyn Ther; 2022 Dec; 40():103058. PubMed ID: 35944846 [TBL] [Abstract][Full Text] [Related]
56. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Unlu S; Kim JW Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885 [TBL] [Abstract][Full Text] [Related]
57. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989 [TBL] [Abstract][Full Text] [Related]
58. Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. Luo ML; Zheng F; Chen W; Liang ZM; Chandramouly G; Tan J; Willis NA; Chen CH; Taveira MO; Zhou XZ; Lu KP; Scully R; Wulf GM; Hu H Cancer Res; 2020 Jul; 80(14):3033-3045. PubMed ID: 32193285 [TBL] [Abstract][Full Text] [Related]
59. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287 [TBL] [Abstract][Full Text] [Related]
60. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency. Maeda J; Haskins JS; Kato TA Mutat Res; 2023; 826():111815. PubMed ID: 36812659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]